Abstract
Corticosteroids are the mainstay treatment for most severe inflammatory disorders. Due to the considerable toxicity associated with their long-term use, there is a great need for alternative treatments. Recently, two closely related neuropeptides with potent neuromodulatory activities, vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase activating peptide (PACAP) have emerged as candidate molecules for the treatment of such pathologies. These peptides act primarily on three high affinity receptor subtypes expressed on multiple immune cell types, and orchestrate a cytokine response that is primarily anti-inflammatory. In this regard, systemic treatment with these peptides has been shown to greatly reduce the clinical symptoms and alter the pathogenic and cytokine profiles in animal models of rheumatoid arthritis, Crohns disease, septic shock, and multiple sclerosis. Likewise, VIP and PACAP receptor knockout and overexpressing mice show altered immune responses in different models. We review here data demonstrating the potential effectiveness of these peptides in immune disorders, discuss receptor pharmacology and signaling pathways, describe the development of receptor specific agonists and antagonists, and discuss pharmaceutical considerations relevant to the specific delivery of analogs to the appropriate targets.
Keywords: pituitary adenylyl cyclase activating peptide (PACAP), Septic shock, Asthma, CIA mice, myelinization, inflammatory diseases
Current Topics in Medicinal Chemistry
Title: Neuropeptide Mimetics and Antagonists in the Treatment of Inflammatory Disease: Focus on VIP and PACAP
Volume: 6 Issue: 2
Author(s): Catalina Abad, Rosa P. Gomariz and James A. Waschek
Affiliation:
Keywords: pituitary adenylyl cyclase activating peptide (PACAP), Septic shock, Asthma, CIA mice, myelinization, inflammatory diseases
Abstract: Corticosteroids are the mainstay treatment for most severe inflammatory disorders. Due to the considerable toxicity associated with their long-term use, there is a great need for alternative treatments. Recently, two closely related neuropeptides with potent neuromodulatory activities, vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase activating peptide (PACAP) have emerged as candidate molecules for the treatment of such pathologies. These peptides act primarily on three high affinity receptor subtypes expressed on multiple immune cell types, and orchestrate a cytokine response that is primarily anti-inflammatory. In this regard, systemic treatment with these peptides has been shown to greatly reduce the clinical symptoms and alter the pathogenic and cytokine profiles in animal models of rheumatoid arthritis, Crohns disease, septic shock, and multiple sclerosis. Likewise, VIP and PACAP receptor knockout and overexpressing mice show altered immune responses in different models. We review here data demonstrating the potential effectiveness of these peptides in immune disorders, discuss receptor pharmacology and signaling pathways, describe the development of receptor specific agonists and antagonists, and discuss pharmaceutical considerations relevant to the specific delivery of analogs to the appropriate targets.
Export Options
About this article
Cite this article as:
Abad Catalina, Gomariz P. Rosa and Waschek A. James, Neuropeptide Mimetics and Antagonists in the Treatment of Inflammatory Disease: Focus on VIP and PACAP, Current Topics in Medicinal Chemistry 2006; 6 (2) . https://dx.doi.org/10.2174/156802606775270288
DOI https://dx.doi.org/10.2174/156802606775270288 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microbial Agent – Fungus
Current Rheumatology Reviews Leptin and Inflammation
Current Immunology Reviews (Discontinued) Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences Different Patterns of Statin Use in Patients with Acute Myocardial Infarction
Current Vascular Pharmacology Retinoid Receptors in Inflammatory Responses: A Potential Target for Pharmacology
Current Drug Targets - Inflammation & Allergy The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy
Current Molecular Medicine The Heme-Heme Oxygenase System in Wound Healing; Implications for Scar Formation
Current Drug Targets The Shift in the “Paradigm” of the Pharmacology of Hypertension
Current Topics in Medicinal Chemistry Phytotherapeutic and Natural Compound Applications for Age-Related, Inflammatory and Serious Eye Ailments
Current Molecular Pharmacology Rescuing inflammation By Inflammasome Inhibitors
Recent Advances in Inflammation & Allergy Drug Discovery Mechanistic Approach to Understanding Psychosis Risk in Velocardiofacial Syndrome
Current Pediatric Reviews Hyponatraemia Associated with Trimethoprim Use
Current Drug Safety αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology
Current Topics in Medicinal Chemistry Epigenetics Changes in the RA Synovium
Current Rheumatology Reviews Stem Cells Differentiation: Organic Chemistry is Back
Letters in Organic Chemistry Carbohydrate-Metal Complexes and their Potential as Anticancer Agents
Current Medicinal Chemistry The Linkage Between Inflammation and Immune Tolerance: Interfering with Inflammation in Cancer
Current Cancer Drug Targets Molecular Hybrids of N-Phthaloylglycyl Hydrazide and Hydrazinecarbothioamide with Anti-inflammatory and Anti-oxidant Activities
Current Organic Synthesis Mast Cells: Target and Source of Neuropeptides
Current Pharmaceutical Design